This report provides all the information you require to better understand Novartis and its partnering interests and activities over the past seven years.

India-based CLARIS Lifesciences Ltd., which operates a generic sterile injectables business, has become the belle of the ball as multi-national companies such as Pfizer Inc., Amneal, Novartis AG and Indian companies such as Lupin and Cipla, are lining up to play the

Novartis , the world’s biggest pharmaceutical (big pharma) company, recently increased its interest in Israel to sign pharma deals. For a long time, the company was active in marketing and clinical trials in Israel, and now it is involved in investment as well.

Novartis is a top pharmaceutical company based in Basel, Switzerland

Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc’s over-the-counter products unit in a deal that could boost earnings at both companies.

Biotech rumor mill has it that since Roche Share Discount Widens on Bet Novartis to Sell Stake for $14.1 billion.

Swiss drugmaker Novartis can spend $4-6 billion per year on m&a to strengthen its core pharma, eyecare and generics businesses or its three smaller units, its chief executive officer said in an interview on Sunday.

Novartis follows the lead of Pfizer and Merck & Co to sell it’s OTC and animal health sector. 

Merger and acquisition rumor mill :Roche Holding AG  founding families want the Swiss drugmaker to stay independent, Chief Executive Officer Severin Schwan said, squelching speculation that circulated since a board member at crosstown rival Novartis AG (NOVN) said last month a merger could make sense

In dealtalk, Novartis plans to exit an eight-year-old vaccines joint venture with India’s Panacea Biotec and intends to go it alone.

Novartis Chairman Joerg Reinhardt said a $10 billion purchase is possible as the drugmaker reviews its business, including units focused on animal health and vaccines, according to dealtalk.

Aduro Biotech announced the establishment of a major collaboration with Novartis

Arrowhead Research announced the acquisition of Novartis’ entire RNAi research and development portfolio and associated assets

Aspen has entered into an agreement with Novartis in terms of which it will acquire the rights to Mono-Embolex

Array BioPharma has reached a definitive agreement with Novartis Pharma to acquire worldwide rights to encorafenib

Novartis Pharmaceuticals announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies

BioLineRx has entered into a multi-year strategic collaboration agreement with Novartis Pharma designed to facilitate development and commercialization of Israeli-sourced drug candidates

Array BioPharma has reached a definitive agreement with Novartis to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials

Novartis announced has entered an agreement that CSL has acquired its influenza vaccine business in a $275 million deal that will require regulatory approval before it closes by the end of the second half of 2015.

Oxford BioMedica has struck a pharma licensing deal worth $90 million with Novartis to manufacture goods that are needed for a highly experimental cancer research program.

Pfizer has signed a pharma deal to promote two new drugs developed by Novartis.